Cerenis and Novasep awarded €10.7 million funding from the French Government for the development CER-001, an HDL mimetic

27-Jul-2010 - France

Cerenis Therapeutics SA and Groupe Novasep announced that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.

CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown strong preclinical efficacy in promoting reverse lipid transport, a natural cardioprotective mechanism by which excess lipids are removed from peripheral tissues and from within atherosclerotic plaques then taken to the liver for elimination. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.

The funding from OSEO will allow the further progression of Cerenis’ novel HDL therapy for orphan disease applications, which represent a large area of unmet need and the potential for an accelerated development pathway.

Cerenis and Novasep have collaborated on the process development for CER-001 since 2007, focusing on downstream processing of the recombinant protein component. Under this funding and an expanded agreement, Novasep will be responsible for the global manufacturing of clinical and initial commercial supplies for the orphan drug development program.

https://www.bionity.com/en/news/120609/cerenis-and-novasep-awarded-10-7-million-funding-from-the-french-government-for-the-development-cer-001-an-hdl-mimetic.html